WO2018086550A1 - 一种生物学活性组分结肠靶向组合物及其应用 - Google Patents
一种生物学活性组分结肠靶向组合物及其应用 Download PDFInfo
- Publication number
- WO2018086550A1 WO2018086550A1 PCT/CN2017/110074 CN2017110074W WO2018086550A1 WO 2018086550 A1 WO2018086550 A1 WO 2018086550A1 CN 2017110074 W CN2017110074 W CN 2017110074W WO 2018086550 A1 WO2018086550 A1 WO 2018086550A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactobacillus
- active component
- biologically active
- colon
- bifidobacterium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 41
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 41
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 30
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 239000002671 adjuvant Substances 0.000 claims abstract 2
- 210000001072 colon Anatomy 0.000 claims description 36
- 229960003943 hypromellose Drugs 0.000 claims description 28
- 239000006041 probiotic Substances 0.000 claims description 26
- 235000018291 probiotics Nutrition 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 18
- 230000000529 probiotic effect Effects 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- 230000008685 targeting Effects 0.000 claims description 13
- 241000186660 Lactobacillus Species 0.000 claims description 12
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 11
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 11
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 9
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 9
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 9
- 241001608472 Bifidobacterium longum Species 0.000 claims description 8
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 4
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 241000194032 Enterococcus faecalis Species 0.000 claims description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 2
- 244000199866 Lactobacillus casei Species 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 2
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 2
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 229940017800 lactobacillus casei Drugs 0.000 claims description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 241000186604 Lactobacillus reuteri Species 0.000 claims 1
- 229940001882 lactobacillus reuteri Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 238000001727 in vivo Methods 0.000 abstract description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 239000000843 powder Substances 0.000 description 23
- 241000894006 Bacteria Species 0.000 description 15
- 238000004090 dissolution Methods 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 210000000813 small intestine Anatomy 0.000 description 12
- 238000012377 drug delivery Methods 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 210000004051 gastric juice Anatomy 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 230000000112 colonic effect Effects 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 240000001717 Vaccinium macrocarpon Species 0.000 description 2
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 2
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 2
- 229960004977 anhydrous lactose Drugs 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000004634 cranberry Nutrition 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000490494 Arabis Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- -1 etc.) Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Definitions
- Biologically active components are a large class of physiologically active components that, through the acquisition of appropriate biologically active components, can play an important role in nutritional improvement, disease prevention and treatment, and health care.
- most of the biologically active components often have the following problems when administered orally: 1) the upper digestive tract environment (such as gastric acid, digestive enzymes, etc.) has considerable destructive activity on the activity of most biologically active components, As for the active components, the active components cannot fully exert the corresponding effects; 2) the biologically active components are abundantly present in the stomach and small intestine after oral administration, and are not advantageously absorbed and utilized by the human body, thereby easily causing corresponding harm to the body; 3) harsh Production and processing conditions (such as temperature, humidity, introduction of some solvents, etc.) have a destructive effect on the activity of the components.
- colon-targeted drug delivery systems are mainly divided into time-delay drug delivery systems, pH-dependent drug delivery systems, enzyme-activated drug delivery systems, pressure-dependent drug delivery systems, and prodrugs.
- Type drug delivery system The time-delayed drug delivery system uses the substance to pass through the stomach and the small intestine to reach the colon in turn, which requires a time lag of 5 to 6 hours, so that the drug is not released in the stomach and small intestine, and is released only after reaching the colon; the pH-dependent drug delivery system is utilized.
- the bioavailability of the fractions is better at exerting its in vivo activity, thereby solving the above problems in the prior art.
- the present invention provides a bioactive component colon targeting composition based on hypromellose (HPMC), comprising: hypromellose, a biologically active component, and an excipient, wherein The hypromellose content is from 10 to 99% by weight, the biologically active component is from 1 to 60% by weight, and the excipient is from 0 to 80% by weight; further preferably, The weight ratio of the hypromellose is 40 to 90%, the weight percentage of the biologically active component is 10 to 40%, and the weight percentage of the auxiliary material is 0 to 50%; Wherein the hypromellose has a viscosity of >1000 mPa.s.
- HPMC hypromellose
- the hypromellose has a viscosity of from 15,000 mPa.s to 200,000 mPa.s.
- the biologically active component is a microorganism; more preferably, the microorganism is a probiotic,
- the probiotic includes one or more of Bifidobacterium, Lactobacillus or Gram-positive cocci which are allowed to be used in foods, health care products and pharmaceuticals; preferably, the Bifidobacterium is Bifidobacterium lactis, infant One or more of Bifidobacterium, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium breve, and Bifidobacterium adolescentis; the Lactobacillus is Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus crispum, Lactobacillus delbrueckii subsp.
- the excipient comprises nutrients which are beneficial to the survival stability of the biologically active component
- the nutrient may be a prebiotic (such as oligofructose, galactooligosaccharide, xylooligosaccharide, oligofructose, soybean) Oligosaccharides, pectins, inulin and cranberry powder, etc.), vitamins and/or sugar alcohols.
- a biologically active component colon targeting composition of the invention for the preparation of a biologically active component colon targeted formulation.
- Figure 2 Dissolution profiles of tablets prepared with hypromellose of different viscosities after sequential application of artificial gastric juice for 2 h, artificial intestinal fluid for 3 h, and artificial colonic fluid for 18 h.
- the probiotic powder used in the present invention includes: Bifidobacterium lactis BLa80, Bifidobacterium longum BL21, Lactobacillus acidophilus LA85 and Bifidobacterium bifidum BBi32, which are derived from Jiangsu Zishi Weikang Biotechnology Co., Ltd.; Lactobacillus licheniformis R11, Bifidobacterium longum R175 and Bifidobacterium lactis lafti B84, which are from the French company LALLEMAND.
- Hypromellose K4M, K15M, K100M used Originated from Anhui Shanhe Accessories Co., Ltd., the hypromellose K100LV and K200M used are from Dow Chemical.
- the mixture powder is directly dry-pressed into tablets, the tablet weight is 300 mg, the tablet diameter is 10 mm, the viable count of Bifidobacterium lactis is 2.5*10 10 cfu/g, and the viable count of Bifidobacterium longum is 3.75* 10 10 cfu/g.
- Si Liankang tablets (Bifidobacterium quadruple live bacteria tablets, 500mg/tablet, wherein Bifidobacterium infantis, Lactobacillus acidophilus and Enterococcus faecalis are not less than 0.5*10 6 cfu/g, respectively, waxy The Bacillus is not less than 0.5*10 5 cfu/g, and the auxiliary material is starch and milk powder.)
- the tablets prepared in the above examples are dissolved and tested for viable count.
- the culture medium is placed in a water bath at 52 ° C for use, and the culture dish is placed at room temperature for cooling.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Animal Husbandry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physiology (AREA)
Abstract
一种生物学活性组分结肠靶向组合物及其制剂和制备方法,该生物学活性组分结肠靶向组合物包括:重量百分含量为10-99%的羟丙甲纤维素、重量百分含量为1-60%的生物学活性组分和重量百分含量为0-80%的辅料,其中羟丙甲纤维素的粘度>1000mPa.s。该生物学活性组分结肠靶向组合物具有改进的结肠靶向效果,提高了生物学活性组分的生物利用度和体内活性。
Description
本发明属于食品、保健品与药品技术领域,具体涉及一种生物学活性组分结肠靶向组合物、其制剂和它们的制备方法。
生物学活性组分是一大类具有生理活性的组分,通过获取适当的生物学活性组分,可对营养的改善、疾病的预防和治疗以及保健起到重要作用。然而,大多数的生物学活性组分经口服时往往存在以下问题:1)上消化道环境(如胃酸、消化酶等)对大部分生物学活性组分的活性具有相当大的破坏力,以至于这些活性组分不能充分发挥相应作用;2)生物学活性组分经口服后大量存在于胃及小肠,无法被人体有利地吸收和利用,从而容易对机体产生相应的危害;3)苛刻的生产加工条件(如温度、湿度、一些溶剂的引入等)对组分活性有破坏作用。
基于上述问题,结肠靶向传递***通过使用适当的方法,能避免有效物质在胃、十二指肠、空肠和回肠释放,直接运送到患者的结肠部位释放,可提高有效物质在结肠部位的局部浓度,便于充分吸收、充分发挥治疗和保健作用,避免在胃及小肠的释放,降低不良反应,提高易被胃酸破坏或易被胃蛋白酶、胰酶代谢的有效物质的生物利用度,从而大大弥补了上述不足。
结合现代药物制剂技术来设计剂型,结肠靶向给药传递***主要分为时滞型释药***、pH依赖型释药***、酶触发型释药***、压力依赖型释药***及前体药物型释药***。时滞型释药***利用物质口服依次经过胃、小肠到达结肠需要5~6h的时滞特点而使药物在胃、小肠不释放,而到达结肠后才开始释放;pH依赖型释药***是利用胃肠道pH条件的不同,通过选择包衣方法,以达到结肠释放目的,包衣制备过程较复杂,需使用溶剂且溶剂需要在一定的温度下挥发干净,该方法很可能导致生物学活性组分的活力显著下降。酶触发型释药***、压力依赖型释药***以及前体药物型释药***目前虽受重视,但三者的非常规性的限制、内在复杂性,甚至是需要专业化的装置和复杂的处理步骤不仅增加了研发过程的复杂性,并且大大降低了产品大规模生产的可能性。
生物学活性组分,特别是有益微生物的活性难以耐受相关制剂制备过程中稍高温度或湿度、溶剂或者其他物质的影响,因此其结肠靶向传递***的研究和开发受到极大的限制,往往越是复杂的制备工艺对其活性的破坏越大,因而
迄今为止尚未见到结肠靶向的益生菌相关产品面市。
现有的益生菌制剂技术能使得益生菌绕过胃而在小肠中释放,但即便是这样,若益生菌在小肠中过多地聚集,也会出现严重的肠道菌群失调等安全性问题(CN200910229403.2)。现有的益生菌制剂技术虽能将益生菌递送到胃肠道的远端区段(包括回肠),但却并非能直接定位递送到结肠,因此益生菌的利用率并不能达到最佳(US2016022592)。现有的益生菌制剂技术还存在所用辅料的安全性问题(ALBERTINI B,VITALI B,PASSERINI N,et al.Development of microparticulate systems for intestinal delivery of Lactobacillus acidophilus and Bifidobacterium lactis[J].European Journal of Pharmaceutical Sciences,2010,40(4):359-366.)。现有的益生菌制剂技术无法避免制备过程中所用溶剂以及制备时升高的温度、湿度等对益生菌活性的影响(KLEMMER K J,KORBER D R,NICHOLAS H,et al.Pea proteinbased capsules for probiotic and prebiotic delivery[J].International Journal of Food Science and Technology,2011,46(11):2248-2256.)。现有的益生菌制剂技术为了满足有效口服剂型的条件,往往所需用的辅料体积较大,载活菌数较低。现有的益生菌制剂技术制备工艺复杂,难以工业化生产(CALINESCU C,MATEESCU M A.Carboxymethyl high amylase starch:chitosan self-stabilized matrix for probiotic colon delivery[J].European Journal of Pharmaceutics and Biopharmaceutics,2008,70(2):582-589.)。
发明内容
本发明的目的是提供一种生物学活性组分的结肠靶向组合物及含有该组合物的制剂,它们能够经过胃和小肠、大部分在到达结肠部位后才释放,从而提高生物学活性组分的生物利用度,更好地发挥其体内活性,从而解决现有技术存在的上述问题。
本发明是通过以下方式实现的:
一方面,本发明提供了一种基于羟丙甲纤维素(HPMC)的生物学活性组分结肠靶向组合物,包括:羟丙甲纤维素、生物学活性组分和辅料,其中,所述羟丙甲纤维素的重量百分含量为10~99%,所述生物学活性组分的重量百分含量为1~60%,辅料的重量百分含量为0~80%;进一步优选地,所述羟丙甲纤维素的重量百分含量为40~90%,所述生物学活性组分的重量百分含量为10~40%,所述辅料的重量百分含量为0~50%;其中,所述羟丙甲纤维素的粘度>1000mPa.s。
优选地,所述羟丙甲纤维素的粘度为15000mPa.s-200000mPa.s。
优选地,所述生物学活性组分为微生物;更优选地,所述微生物为益生菌,
所述益生菌包括食品、保健品和药品中允许使用的双歧杆菌、乳杆菌或革兰氏阳性球菌中的一种或多种;优选地,所述双歧杆菌是乳双歧杆菌、婴儿双歧杆菌、两歧双歧杆菌、长双歧杆菌、短双歧杆菌和青春双歧杆菌中的一种或多种;所述乳杆菌是嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、德氏乳杆菌保加利亚亚种(保加利亚乳杆菌)、德氏乳杆菌亚种、发酵乳杆菌、格氏乳杆菌、瑞士乳杆菌、约氏乳杆菌、副干酪乳杆菌、植物乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、唾液乳杆菌中的一种或多种;所述革兰氏阳性球菌是粪链球菌和乳球菌中的一种或多种。
进一步优选地,所述结肠靶向组合物中益生菌的量为0.01亿-1200亿cfu/g。
优选地,所述辅料包括有利于生物学活性组分生存稳定性的营养物质,该营养物质可以为益生元(如低聚果糖、低聚半乳糖、低聚木糖、低聚乳果糖、大豆低聚糖、果胶、菊粉和蔓越莓粉等)、维生素和/或糖醇。
优选地,所述辅料还包括果胶、海藻酸钠、壳聚糖等对生物学活性组分的结肠靶向递送有益的药用辅料或食品添加剂。
优选地,所述辅料还包括其他粘合剂(***胶、瓜尔胶、藻酸、羟甲基纤维素、糊精、卡波姆、麦芽糖、明胶、葡萄糖、乙基纤维素、甲基纤维素、聚环氧乙烷或聚维酮)、填充剂(淀粉、可压性淀粉、变性淀粉、山梨醇、甘露醇、微晶纤维素、糖粉、糊精、无机盐、无水乳糖、乳酸钙)、润滑剂(硬脂酸镁、硬脂酸、矿物油、聚乙二醇、滑石粉、二氧化硅)、崩解剂(羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲纤维素钠、交联聚维酮、干淀粉)等可优化制剂本身性质的其它辅料。
第二方面,本发明提供了一种生物学活性组分结肠靶向制剂,它包含本发明的生物学活性组分结肠靶向组合物。
优选地,所述制剂的剂型为片剂;更优选地,为便于吞服,所述片剂单片质量≤500mg,直径≤10mm。这种剂型可以进一步帮助生物学活性组分在具有大量菌群的结肠中释放,而在胃、小肠和回肠仅部分或少量释放。
第三方面,提供了本发明的生物学活性组分结肠靶向组合物在制备生物学活性组分结肠靶向制剂中的应用。
第四方面,提供了本发明的生物学活性组分结肠靶向制剂的制备方法,包括:
(1)在操作温度<28℃、湿度<40%下,将羟丙甲纤维素、生物学活性组分和辅料混合;
(2)将混合物直接干压成片剂,或干法制粒后压成片剂。
本发明首次将羟丙甲纤维素与生物学活性组分结合,利用羟丙甲纤维素缓
释特性和粘合作用即可经粉末直接干压或干法制粒后压片,从而制得生物学活性组分结肠靶向片剂,避免了湿法制粒和现有结肠靶向相关文献中常见的包衣方法所用的溶剂及温度对生物学活性组分活性的不利影响,且制备工艺简单,易于产业化。所制备的生物学活性组分结肠靶向片剂与市售生物学活性组分片剂相比,由于羟丙甲纤维素的多重作用,可使生物学活性组分经过胃和小肠、到达结肠部位后才释放,耐受胃和小肠环境而不被代谢分解,减小其对小肠可能产生的危害因素,提高生物学活性组分的生物利用度,从而更好地发挥体内活性。特别地就益生菌制剂而言,还可大大减少其他辅料的使用,从而显著提高每片片剂的载菌量,使得日服用量由市售常见的9片以上降至1-2片,并且片形可以更小,更便于吞服。
与现有技术相比,本发明的组合物具有显著改进的结肠靶向效果;此外,可采用食品级辅料,具有极高的安全性;能够便于工业化生产,工艺简单。因此,本发明对于食品、保健品和药品行业均具有重大的开发意义。
图1:实施例1-7的片剂在依次经过人工胃液2h、人工肠液3h、人工结肠液18h后的溶出曲线图。
图2:不同粘度的羟丙甲纤维素制备的片剂在依次经过人工胃液2h、人工肠液3h、人工结肠液18h后的溶出曲线图。
以下通过具体实施例对本发明技术方案及其效果做进一步说明。应当理解,本发明实施例仅用于示例说明本发明的具体实施方法,并不用于限制本发明的保护范围。应用本发明的构思对本发明进行的简单改进都在本发明要求保护的范围内。
如无特别说明,以下实施例中使用的试剂和仪器均是常规试剂和仪器,可以从普通商购途径获得;所使用的操作方法是本领域的常规方法,本领域技术人员结合自己的认知水平和实验能力,能够实现本文所述的实验过程并获得相应的结果。
本发明中所用的益生菌菌粉包括:乳双歧杆菌BLa80、长双歧杆菌BL21、嗜酸乳杆菌LA85和两歧双歧杆菌BBi32,它们来源于江苏紫石微康生物科技有限公司;鼠李糖乳杆菌R11、长双歧杆菌R175和乳双歧杆菌lafti B84,它们来源于法国LALLEMAND公司。所用的羟丙甲纤维素K4M、K15M、K100M
来源于安徽山河辅料有限公司,所用羟丙甲纤维素K100LV和K200M来源于美国陶氏化学。
实施例1
处方:羟丙甲纤维素(HPMC K15M,粘度15000mPa.s)85wt%,乳双歧杆菌BLa80菌粉(活菌数1.0*1011cfu/g)15wt%。
制备方法:
(1)将各物料按处方量混合均匀、过100目筛子,再使之均匀混合;
(2)将粉末混合物用GL2-25型干法制粒机(张家港开创机械制造公司)进行制粒后,压片,单片重150mg,片直径8mm,所含乳双歧杆菌活菌数为1.5*1010cfu/g。
实施例2
处方:羟丙甲纤维素(HPMC K200M,粘度200000mPa.s)65wt%,鼠李糖乳杆菌R11菌粉(活菌数1.5*1011cfu/g)30wt%,硬脂酸镁5wt%。
制备方法:
(1)将各物料按处方量混合均匀;
(2)将该混合物粉末直接干压成片剂,片重450mg,片直径10mm,所含鼠李糖乳杆菌活菌数为4.5*1010cfu/g。
实施例3
处方:羟丙甲纤维素(HPMC K100M,粘度100000mPa.s)65wt%,嗜酸乳杆菌LA85菌粉(活菌数1.0*1011cfu/g)30wt%,硬脂酸镁5wt%。
制备方法:
(1)将各物料按处方量混合均匀;
(2)将该混合物粉末直接干压成片剂,片重300mg,片直径10mm,所含嗜酸乳杆菌活菌数为3.0*1010cfu/g。
实施例4
处方:羟丙甲纤维素(HPMC K200M,粘度200000mPa.s)45wt%,乳双歧杆菌BLa80菌粉(活菌数1.0*1011cfu/g)25wt%,长双歧杆菌BL21菌粉(活菌数1.5*1011cfu/g)25wt%,硬脂酸镁5wt%。
制备方法:
(1)将各物料按处方量混合均匀;
(2)将该混合物粉末直接干压成片剂,片重300mg,片直径10mm,所含乳双歧杆菌活菌数为2.5*1010cfu/g,长双歧杆菌活菌数为3.75*1010cfu/g。
实施例5
处方:羟丙甲纤维素(HPMC K4M,粘度4000mPa.s)70wt%,无水乳糖20wt%,麦芽糖醇5wt%,两歧双歧杆菌BBi32菌粉(活菌数1.5*1011cfu/g)3wt%,二氧化硅1wt%,硬脂酸镁1wt%。
制备方法:
(1)将各物料按处方量混合均匀;
(2)将该混合物粉末直接干压成片剂,片重300mg,片直径10mm,所含两歧杆菌活菌数为4.5*109cfu/g。
实施例6
处方:羟丙甲纤维素(HPMC K100M,粘度100000mPa.s)13wt%,长双歧杆菌R175菌粉(活菌数5*1010cfu/g)30wt%,异麦芽酮糖醇25wt%,菊粉15wt%,乳酸钙10wt%,果胶5wt%,硬脂酸镁2wt%。
制备方法:
(1)将各物料按处方量混合均匀;
(2)将该混合物粉末直接干压成片剂,片重300mg,片直径10mm,所含长双歧杆菌活菌数为1.5*1010cfu/g。
实施例7
处方:羟丙甲纤维素(HPMC K100M,粘度100000mPa.s)45wt%,低聚果糖20wt%,嗜乳酸杆菌R418菌粉(活菌数1.5*1011cfu/g)15wt%,乳双歧杆菌lafti B84菌粉(活菌数1*1011cfu/g)10wt%,蔓越莓粉5wt%,山梨糖醇5wt%。
制备方法:
(1)将各物料按处方量混合均匀;
(2)混合物粉末用干法制粒机制粒后,压片,片重450mg,片直径10mm,所含嗜乳酸杆菌活菌数为2.25*1010cfu/g,所含乳双歧杆菌活菌数为1.0*1010cfu/g。
实验例一:本发明实施例的溶出试验
由于益生菌对温度和水均敏感,溶出试验需要取不同时间点的溶出液,因
此以考察结肠释药性的模型药物5-氨基水杨酸代替益生菌进行试验。按照中国药典(2015年版四部0931溶出度与释放度测定法第一法转篮法,50r/min,37℃,将利用上述实施例中的方法和处方制备的片剂(以5-氨基水杨酸代替相应量的益生菌)放入转篮中,依次进行人工胃液(pH1.2)2h、人工肠液(pH6.8)3h、人工结肠液(pH7.8)18h后的溶出测定。各实施例中片剂的溶出结果见图1,结肠释放百分率见表1。
表1:实施例中片剂结肠释放百分率(%)
实施例 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
片剂的结肠释放百分率(%) | 61 | 81 | 76 | 55 | 45 | 58 | 74 |
由图1和表1结果可知:实施例1-7的片剂的结肠释放百分率均可达45%以上,具有显著的结肠靶向效果。
实验例二:不同粘度羟丙甲纤维素片剂的溶出试验
以五种不同粘度的羟丙甲纤维素:HPMC K100LV(粘度:100mPa.s)、K4M、K15M、K100M和K200M,用量均为90wt%,和用量为10wt%的5-氨基水杨酸按本文所述的方法制备片剂和检测溶出结果,结果见图2。图中溶出结果显示:低粘度HPMC(K100LV)制备的片剂经人工胃液和人工肠液后释放即近100%,无法达到结肠释放;而较高粘度HPMC(K4M、K15M、K100M和K200M)制备的片剂在相同条件下可至少保持60%以上在结肠释放,且在人工结肠液中近线性释放,具有显著的结肠靶向效果。
实验例三:活菌数检测实验
以市售思连康片剂(双歧杆菌四联活菌片,500mg/片,其中婴儿双歧杆菌、嗜酸乳杆菌和粪肠球菌分别不低于0.5*106cfu/g,蜡样芽孢杆菌不低于0.5*105cfu/g,辅料为淀粉和奶粉类物质)与上述实施例制得的片剂溶出后进行活菌数检测。
(一)实验方法
(1)培养基配制
取MRS琼脂粉39.7g,加入600ml蒸馏水中,加热溶解。2.9mm玻璃培养皿用自来水洗净后,再用蒸馏水冲洗三遍,晾干。
(2)灭菌
培养基和培养皿置于灭菌锅中,121℃,103.4kPa灭菌30min。
(3)培养基置于52℃水浴锅中备用,培养皿室温放置冷却备用。
(4)溶出条件
按照中国药典(2015年版四部0931溶出度与释放度测定法第一法转篮法,50r/min,37℃),将市售思连康片剂进行人工胃液(pH1.2)2h后取出,将实施例1-7的片剂放入转篮中,依次进行人工胃液(pH1.2)2h、人工肠液(pH6.8)3h后取出。
(二)培养
取上述未经与经过溶出处理的思连康片剂与实施例1-7的片剂样品,分别置于玻璃研钵中研碎,然后用50ml生理盐水稀释,混匀后取1ml混合液10倍倍比稀释,稀释后取各个稀释度0.1ml涂布于MRS培养基上。将涂布后的平板至于厌氧袋中放在37℃恒温培养箱中培养48h后将平板取出进行菌落计数。
(三)结果
市售思连康片剂经人工胃液(pH 1.2、37℃)2h处理后,在10-4倍稀释仍无菌落数;而实施例1-7的片剂经人工胃液(pH 1.2、37℃)2h、人工肠液(pH 6.8、37℃)3h处理后,活菌数仍较多,与市售思连康片剂相比有显著性差异,具体活菌数检测结果见表2。该比较结果说明,本发明的益生菌片剂使得益生菌可以成功地耐受胃和小肠环境,从而保持其一定的活菌数递送到结肠部位释放,并且本发明对不同厂家来源的不同菌种均可保护其被递送到结肠部位释放。
表2:市售思连康和实施例1-7片剂溶出后活菌数检测结果
Claims (10)
- 一种生物学活性组分结肠靶向组合物,包括:羟丙甲纤维素、生物学活性组分和辅料,其中,所述羟丙甲纤维素的重量百分含量为10~99%,所述生物学活性组分的重量百分含量为1~60%,辅料的重量百分含量为0~80%;其中,所述羟丙甲纤维素的粘度>1000mPa.s。
- 根据权利要求1所述的组合物,其中,所述羟丙甲纤维素的重量百分含量为40~90%,所述生物学活性组分的重量百分含量为10~40%,所述辅料的重量百分含量为0~50%。
- 根据权利要求1或2所述的组合物,其中,所述羟丙甲纤维素的粘度为15000mPa.s~200000mPa.s。
- 根据权利要求3所述的组合物,其中,所述生物学活性组分为微生物,优选为益生菌,更优选地,所述益生菌包括双歧杆菌、乳杆菌或革兰氏阳性球菌中的一种或多种;进一步优选地,所述双歧杆菌是乳双歧杆菌、婴儿双歧杆菌、两歧双歧杆菌、长双歧杆菌、短双歧杆菌和青春双歧杆菌中的一种或多种;所述乳杆菌是嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、德氏乳杆菌保加利亚亚种、德氏乳杆菌亚种、发酵乳杆菌、格氏乳杆菌、瑞士乳杆菌、约氏乳杆菌、副干酪乳杆菌、植物乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、唾液乳杆菌中的一种或多种;所述革兰氏阳性球菌是粪链球菌和乳球菌中的一种或多种。
- 根据权利要求4所述的组合物,其中,所述组合物中益生菌的量优选为0.01亿-1200亿cfu/g。
- 根据权利要求5所述的组合物,其中,所述辅料包括有利于生物学活性组分生存稳定性的营养物质、对生物学活性组分的结肠靶向递送有益的药用辅料或食品添加剂、和/或优化制剂本身性质的其它辅料。
- 一种生物学活性组分结肠靶向制剂,包含权利要求1-6任一项所述的组合物。
- 根据权利要求7所述的生物学活性组分结肠靶向制剂,其中,所述制剂的剂型为片剂;优选地,所述片剂的单片质量≤500mg,直径≤10mm。
- 权利要求1-6任一项的组合物在制备生物学活性组分结肠靶向制剂中的应用。
- 一种制备权利要求8所述的生物学活性组分结肠靶向制剂的方法,包括:(1)在操作温度为<28℃、湿度<40%下,将羟丙甲纤维素、生物学活性组分和辅料混合;(2)将混合物直接干压成片剂,或干法制粒后压成片剂。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17869993.0A EP3539538A4 (en) | 2016-11-11 | 2017-11-09 | AGAINST THE COLUMN-INTESTINE COMPOSITION WITH BIOLOGICALLY ACTIVE COMPONENT AND APPLICATION THEREOF |
US16/349,093 US11337926B2 (en) | 2016-11-11 | 2017-11-09 | Colon-targeted composition of biological active component and application thereof |
RU2019116519A RU2744452C2 (ru) | 2016-11-11 | 2017-11-09 | Композиция для направленной доставки биологически активного компонента в толстую кишку и ее применение |
JP2019546961A JP6989154B2 (ja) | 2016-11-11 | 2017-11-09 | 生物学的活性成分の結腸標的組成物、およびその利用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611013848.3A CN108066296B (zh) | 2016-11-11 | 2016-11-11 | 一种生物学活性组分结肠靶向组合物及其应用 |
CN201611013848.3 | 2016-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018086550A1 true WO2018086550A1 (zh) | 2018-05-17 |
Family
ID=62109436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/110074 WO2018086550A1 (zh) | 2016-11-11 | 2017-11-09 | 一种生物学活性组分结肠靶向组合物及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11337926B2 (zh) |
EP (1) | EP3539538A4 (zh) |
JP (1) | JP6989154B2 (zh) |
CN (1) | CN108066296B (zh) |
RU (1) | RU2744452C2 (zh) |
WO (1) | WO2018086550A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115644448A (zh) * | 2022-09-07 | 2023-01-31 | 西安诺众康健生物科技有限责任公司 | 一种肠道益生菌包埋保护方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10966440B2 (en) * | 2019-01-05 | 2021-04-06 | Foremost Technologies and Products, Inc. | High pressure processing of foods and food supplements |
CN109652349B (zh) * | 2019-02-25 | 2021-03-02 | 江南大学 | 一株能够缓解特应性皮炎的长双歧杆菌及其应用 |
CN113274369B (zh) * | 2021-04-29 | 2022-10-14 | 暨南大学 | 一种结肠靶向的口服益生菌微囊及其制备方法与应用 |
CN114703102B (zh) * | 2022-04-19 | 2023-05-05 | 微康益生菌(苏州)股份有限公司 | 一种缓解便秘的两歧双歧杆菌及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1853655A (zh) * | 2005-04-28 | 2006-11-01 | 杨明 | 一种治疗溃疡性结肠炎的口服结肠靶向制剂及其制备方法 |
CN1921838A (zh) * | 2004-02-19 | 2007-02-28 | 兰贝克赛实验室有限公司 | 双丙戊酸钠的缓释药物组合物 |
CN102106925A (zh) * | 2009-12-28 | 2011-06-29 | 于莲 | 枸杞多糖双歧杆菌合生元结肠靶向微生态调节剂 |
CN105120847A (zh) * | 2013-03-14 | 2015-12-02 | 塞拉拜姆有限责任公司 | 益生生物和/或治疗剂的靶向胃肠道递送 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024412A2 (en) * | 1996-12-05 | 1998-06-11 | The Board Of Trustees Of The University Of Illinois | Compounds useful against diseases of the colon and methods for orally administering same |
US20070098784A1 (en) * | 2001-09-28 | 2007-05-03 | Nutraceutix, Inc. | Delivery system for biological component |
CN101843337B (zh) * | 2010-06-07 | 2012-10-10 | 陕西科技大学 | 一种益生菌片的制备方法 |
JP5087167B2 (ja) * | 2010-12-28 | 2012-11-28 | フロイント産業株式会社 | ビフィズス菌大腸デリバリーカプセル及びその製造方法 |
ITMI20132065A1 (it) * | 2013-12-11 | 2015-06-12 | Farmatron Ltd | Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali |
SG11201610250WA (en) * | 2014-07-01 | 2017-01-27 | Probi Usa Inc | Bi-layer dual release probiotic tablets |
-
2016
- 2016-11-11 CN CN201611013848.3A patent/CN108066296B/zh active Active
-
2017
- 2017-11-09 EP EP17869993.0A patent/EP3539538A4/en active Pending
- 2017-11-09 US US16/349,093 patent/US11337926B2/en active Active
- 2017-11-09 RU RU2019116519A patent/RU2744452C2/ru active
- 2017-11-09 JP JP2019546961A patent/JP6989154B2/ja active Active
- 2017-11-09 WO PCT/CN2017/110074 patent/WO2018086550A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1921838A (zh) * | 2004-02-19 | 2007-02-28 | 兰贝克赛实验室有限公司 | 双丙戊酸钠的缓释药物组合物 |
CN1853655A (zh) * | 2005-04-28 | 2006-11-01 | 杨明 | 一种治疗溃疡性结肠炎的口服结肠靶向制剂及其制备方法 |
CN102106925A (zh) * | 2009-12-28 | 2011-06-29 | 于莲 | 枸杞多糖双歧杆菌合生元结肠靶向微生态调节剂 |
CN105120847A (zh) * | 2013-03-14 | 2015-12-02 | 塞拉拜姆有限责任公司 | 益生生物和/或治疗剂的靶向胃肠道递送 |
US20160022592A1 (en) | 2013-03-14 | 2016-01-28 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
Non-Patent Citations (4)
Title |
---|
ALBERTINI BVITALI BPASSERINI N ET AL.: "Development of microparticulate systems for intestinal delivery of Lactobacillus acidophilus and Bifidobacterium lactis [J", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 40, no. 4, 2010, pages 359 - 366, XP027066416, DOI: doi:10.1016/j.ejps.2010.04.011 |
CALINESCU CMATEESCU M A: "Carboxymethyl high amylase starch: chitosan self-stabilized matrix for probiotic colon delivery [J", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 70, no. 2, 2008, pages 582 - 589 |
KLEMMER K JKORBER D RNICHOLAS H ET AL.: "Pea proteinbased capsules for probiotic and prebiotic delivery [J", INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, vol. 46, no. 11, 2011, pages 2248 - 2256, XP055187943, DOI: doi:10.1111/j.1365-2621.2011.02743.x |
See also references of EP3539538A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115644448A (zh) * | 2022-09-07 | 2023-01-31 | 西安诺众康健生物科技有限责任公司 | 一种肠道益生菌包埋保护方法 |
Also Published As
Publication number | Publication date |
---|---|
US11337926B2 (en) | 2022-05-24 |
RU2744452C2 (ru) | 2021-03-09 |
JP6989154B2 (ja) | 2022-01-05 |
CN108066296B (zh) | 2020-11-17 |
CN108066296A (zh) | 2018-05-25 |
RU2019116519A (ru) | 2020-12-11 |
RU2019116519A3 (zh) | 2020-12-11 |
US20190274960A1 (en) | 2019-09-12 |
EP3539538A1 (en) | 2019-09-18 |
JP2020500927A (ja) | 2020-01-16 |
EP3539538A4 (en) | 2020-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018086550A1 (zh) | 一种生物学活性组分结肠靶向组合物及其应用 | |
TWI574633B (zh) | 包含益生菌及益生質成分及礦物鹽及乳鐵蛋白之組合物 | |
CN111246839A (zh) | 用于治疗艰难梭菌感染的新用途 | |
CN104413334A (zh) | 可食用组合物及其制备方法和用途 | |
WO1999064023A1 (fr) | Compositions contenant des bacteries lactiques, medicaments et aliments | |
JP6637725B2 (ja) | ウイルス感染症の予防及び/又は治療剤 | |
JP5735548B2 (ja) | プロバイオティクス製剤ならびに5−ht4受容体作動薬を含有する経口投与用複合製剤、及びその製造方法 | |
CN101897729A (zh) | 一种益生菌组合物及其制剂 | |
Nader‐Macías et al. | Probiotic lactobacilli in formulas and hygiene products for the health of the urogenital tract | |
Lokhande et al. | A systematic study of probiotics-an update review | |
CN110193029B (zh) | 益生菌的结肠靶向给药方法 | |
CN113425696B (zh) | 一种复方口服补液盐的泡腾制剂及其制备工艺和应用 | |
JP5681533B2 (ja) | 消化管痛の予防又は軽減剤 | |
CN107073048B (zh) | 含有乳酸菌的组合物 | |
CN107002023B (zh) | 拟杆菌在治疗或预防肥胖相关疾病中的用途 | |
JP5415232B2 (ja) | 生菌製剤の製造方法 | |
JP4603116B2 (ja) | 乳酸菌含有組成物、医薬及び食品 | |
RU2491079C1 (ru) | Комплексный пробиотический препарат и способ его получения | |
JP5940869B2 (ja) | 腸内環境改善有核錠製剤及びハードカプセル製剤 | |
WO2015140299A1 (en) | Oronasopharyngeal probiotics | |
JP5631721B2 (ja) | 胃腸機能亢進剤 | |
JP2005247775A (ja) | 予防・治療用栄養組成物 | |
JP2019116447A (ja) | 固形製剤及びその製造方法 | |
Ullah et al. | Prebiotics and Probiotics: Concept and Advances | |
JP2016108303A (ja) | 神経機能改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17869993 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019546961 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017869993 Country of ref document: EP Effective date: 20190611 |